title: Low doses of intracoronary enalaprilat suppress reperfusion-associated ventricular arrhythmias after primary percutaneous coronary interventions for acute myocardial infarction.
abstract: BACKGROUND
  In the era of early reperfusion therapy, life-threatening ventricular arrhythmias (VA) remain common after recanalization of an occluded coronary artery. Experimental studies reported that angiotensin-converting (ACE) inhibitors suppress reperfusion-induced VA. However, whether ACE inhibitors lower the incidence of reperfusion clinical VA is unknown. We examined the effects of low doses of intracoronary (i.c.) enalaprilat (EN) as an adjunct to direct percutaneous coronary interventions (PCI) on reperfusion VA in the acute phase of myocardial infarction (MI).
  
  
  METHODS
  We randomly assigned 22 patients with a first acute MI, who underwent successful direct PCI, to EN, 50 mug, i.c., or placebo (PL), administered immediately after reperfusion. VA were manually edited and counted from 24-hour Holter recordings begun upon hospital admission.
  
  
  RESULTS
  There were no significant between-groups differences in clinical characteristics. Mean RR interval before and after PCI, and the incidence of VA before PCI were similar in both groups. After PCI the incidence of reperfusion-induced VA was significantly lower in the EN-treated group (VPB/h: PL 29.9 +/- 12 vs EN 43.2 +/- 42, P < 0.05; couplets/h: EN 0.9 +/- 0.7 vs PL 4.1 +/- 5.0, P < 0.01; triplets/h: EN 0.3 +/- 0.2 vs PL 1.2 +/- 1.5, P < 0.05; ventricular tachycardia/h: EN 0.3 +/- 0.1 vs PL 0.8 +/- 0.5, P < 0.01).
  
  
  CONCLUSIONS
  Compared with PL, i.c. EN significantly lowered the incidence of reperfusion-associated VA. This previously unrecognized antiarrhythmic effect might be an important therapeutic benefit conferred by ACE inhibitors, beyond limitation of infarct size.
authors.affiliation: Medizinische Klinik II, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany. Bonnemei@medinf.mu-luebeck.de
authors.forename: Hendrik
authors.initials: H
authors.lastname: Bonnemeier
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schäfer
authors.forename: Jasmin
authors.initials: J
authors.lastname: Ortak
authors.forename: Thomas
authors.initials: T
authors.lastname: Kurz
authors.forename: Hugo A
authors.initials: HA
authors.lastname: Katus
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
authors.forename: Heribert
authors.initials: H
authors.lastname: Schunkert
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy*; D004656:Enalapril / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D015425:Myocardial Reperfusion; D011446:Prospective Studies
chemical_list: D000959:Antihypertensive Agents; D004656:Enalapril